Feng Chi Biotech (ROCO:6744) Debt-to-Equity : 0.05 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Feng Chi Biotech Debt-to-Equity?

Feng Chi Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$2.6 Mil. Feng Chi Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$8.1 Mil. Feng Chi Biotech's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$238.0 Mil. Feng Chi Biotech's debt to equity for the quarter that ended in Dec. 2023 was 0.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Feng Chi Biotech's Debt-to-Equity or its related term are showing as below:

ROCO:6744' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.04 Max: 0.06
Current: 0.05

During the past 8 years, the highest Debt-to-Equity Ratio of Feng Chi Biotech was 0.06. The lowest was 0.01. And the median was 0.04.

ROCO:6744's Debt-to-Equity is ranked better than
72.98% of 1066 companies
in the Biotechnology industry
Industry Median: 0.145 vs ROCO:6744: 0.05

Feng Chi Biotech Debt-to-Equity Historical Data

The historical data trend for Feng Chi Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Feng Chi Biotech Debt-to-Equity Chart

Feng Chi Biotech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.04

0.02

0.01

0.06

0.05

Feng Chi Biotech Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial									0.01	0.01	0.06	0.05	0.05

Competitive Comparison of Feng Chi Biotech's Debt-to-Equity

For the Biotechnology subindustry, Feng Chi Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Feng Chi Biotech's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Feng Chi Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Feng Chi Biotech's Debt-to-Equity falls into.

Feng Chi Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Feng Chi Biotech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.649	+	8.149)	/	237.998
	=	0.05

Feng Chi Biotech's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.649	+	8.149)	/	237.998
	=	0.05

Feng Chi Biotech (ROCO:6744) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Feng Chi Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Feng Chi Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Feng Chi Biotech (ROCO:6744) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Feng Chi Biotech Corp (ROCO:6744) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 5, Shaoxing North Street, 5th Floor-1, Zhongzheng District, Taipei City, TWN, 100

Website

http://www.fcbiotech.com.tw

Feng Chi Biotech Corp provide promotion and support for clinical testing and molecular genetic medicine research related technologies. The company's products and services include clinical testing, food testing, newborn screening, prenatal screening, iron stomach, interscience, and colony counting.

Feng Chi Biotech (ROCO:6744) Headlines

No Headlines